Depression Clinical Trial
Official title:
"Consultation Liaison and Integrated Care for COPD Patients With Psychiatric Co-Morbidity"
Chronic obstructive pulmonary disease (COPD) stands out among chronic diseases with its high
and rising prevalence and mortality, poor quality of life, high re-hospitalization rates and
societal burden of care. Current therapeutic and management practices are generally met with
limited success. Research in recent years have highlighted the high level of psychiatric
co-morbidity in COPD patients, and the major prognostic significance of anxiety/depression in
COPD outcomes such as re-hospitalization, smoking cessation, quality of life, and survival.
This suggests that addressing psychiatric and psycho-social aspects of care prominent in COPD
patients may have strongly positive impact on outcomes, but the available evidence of
effectiveness is limited.
The primary aim of the proposed research is to evaluate the effectiveness of a holistic
disease management paradigm of psychiatric liaison consultation (CL) that integrates
psychiatric and respiratory care to improve outcomes for COPD patients. This integrated
psychiatric consultation liaison (IPCL) management paradigm includes the routine screening
and structured collaborative care of anxiety and major depressive symptoms and
depressive/anxiety disorder in COPD patients. We postulate that the IPCL care paradigm would
reduce mood symptoms, increase smoking quit rates, reduce symptom burden and functional
disability, and improve quality of life, while reducing rehospitalization, emergency
department (ED) and unscheduled physician visits. A secondary aim is to evaluate its cost
effectiveness by concurrently collecting resource utilization data.
Specific Aims
The aim of the proposed research is to evaluate the effectiveness of a holistic disease
management paradigm of) that integrates psychiatric and respiratory care (Integrated
Psychiatric Consultation Liaison, IPCL) that addresses the high level of psychiatric
co-morbidity in COPD patients to improve COPD outcomes.
Methods
Patient population Inpatients and specialist outpatients with established clinical diagnosis
of chronic obstructive pulmonary disease (COPD).
Settings
Hospital based specialist outpatient and inpatient acute care and step-down care facilities
in four hospitals (NUHS, AH, SGH and CGH) and one community hospital (SLH).
The site PIs from each hospital are Lim Tow Keang (NUHS),Loo Chian Min (SGH),K. Narendran
(CGH), Gerald Chua (AH) and Tan Boon Yeow (SLH).
Study design Parallel group, randomized, controlled trial.
Eligible individuals are randomly assigned (1:1 ratio) to either:
1. Integrated Psychiatric Consultation Liaison (IPCL) care (N=450);
2. Usual care. Patients in this group will receive usual standard care (N=450).
Baseline screening and assessment. Prior to randomization to either IPCL or UC arm, COPD
patients are screened for anxiety /depression using the Hospital Anxiety and Depression Scale
(HADS, see below for details).21.For patients with high HADS scores(≥8), a semi-structured
diagnostic assessment will be immediately performed using Structured Clinical Interview for
DSM-IV Axis I Disorders (SCID-I for DSM-IV22 by an advanced practice nurse (APN) and the
provisional diagnosis of anxiety and/or major depressive disorder will be confirmed by a
psychiatrist, Cases with significant anxiety or depressive symptomatology that do not meet
DSM-IV threshold criteria are classified as subsyndromal cases.
Randomization. After informed consent is signed and patient eligibility is confirmed, the
patient will be randomized in a 1:1 ratio to either the intervention arm receiving IPCL care
or the control arm receiving usual care. Stratification by center is used to ensure balance
between the two arms across centers. Random permuted blocks are used to ensure balance over
time. The block length is determined by the study statistician. The patient will be assigned
an individual number upon randomization. This assigned randomized number will identify the
patient and will be used for all documentation for this patient in this study. The list of
randomizations will go through Singapore Clinical Research Institute (SCRI). Randomization
may be done via the following options: (i) Direct web randomization: Authorized study center
personnel will randomize the patient via a password-protected internet web site available 24
hours a day; (ii) Envelope Randomization: In case of web downtime due to technical error,
site personnel may randomize patients using the back-up envelopes that will be provided upon
activation of the site.
IPCL Care Group For patients who are randomly allocated to the IPCL arm,
1. Routine active screening and diagnosis of psychiatric co-morbidity using HADS followed
by appropriate SCID interview by a trained APN, and confirmation by a consultant
psychiatrist, will be performed at 3 monthly intervals during unscheduled and scheduled
outpatient consultation or follow up visits and at each hospital admission.
2. The appropriate management of psychiatric and psycho-social problems will be performed
by a multi-disciplinary care team that includes the respiratory physician, psychiatrist,
advanced practice nurse and nurse clinicians
3. The APN and nurse clinician perform critical roles as case manager and patient educator.
Psychoeducation is a critical care process component that will aim to ensure that the
majority (over 70%) of COPD patients in the IPCL group with psychological symptoms will
accept psycho-social and psychiatric care, in contrast to a large majority of patients
who will conventionally refuse care, particularly in the UC group.
4. The treatment of cases will accord with recommended treatment guidelines for
anxiety/depression, and individualized for each patient according to a treatment plan
drawn up by the psychiatrist, with the agreement of the respiratory physician. Treatment
and care management of mild depressive symptomatology, psycho-social problems, or severe
major depression and/or anxiety disorder will include appropriate pharmacologic and/or
non-pharmacologic therapies (such as cognitive and/or behavioural therapy) and
psycho-social support.
5. Where pharmacologic treatment is indicated, the preferred drugs are SSRI antidepressants
prescribed according to local standard dosages. The recommended first line of treatment
is Fluoxetine, a dose of 20 mg/day or Escitalopram (10 to 20 mg/day). Alternatively,
patients who do not respond to Fluoxetine or Escitalopram after 4 weeks, or who have
intolerable side effects may be prescribed Venlafaxine XR, 75/mg/day, increased to
150-225 mg/day OR Mirtazapine (15mg/day, increased to 30-45 mg/day). If no response,
mood stabilizer or electro convulsive therapy (ECT) or psychosocial intervention will be
added on with the medication (Figure 2).
6. Non-drug psychotherapy will be provided either by the psychiatrist or psychological
counselor where appropriate (for most patients with only depressive or anxiety
symptomatology).
7. The case manager will liaise with medical social worker for financial and other
community services support.
8. The nurse educator will provide standard patient education and behavioural modification
including information about disease and medications for both COPD and depression, and
changing attitudes and behaviour particularly in regard to smoking cessation and
medication adherence, and general psycho-social supportive counseling.
9. Appropriate existing and redesigned treatment algorithms and management protocols will
be put together and provide a sourcebook for drawing up individual care plans.
10. Routine monitoring and outcomes assessments is integrated as part of IPCL care and
performed at 3 or 6 monthly intervals as appropriate: these include perceived symptoms
of breathlessness, exercise tolerance, spirometric measurement (12 month), smoking
cessation, HADS, SGRQ quality of life, acute COPD exacerbations, rehospitalization(s),
emergency department visits, and unscheduled physician visits etc.(see schedule).
11. Ad hoc follow up visits are scheduled at any appropriate times for therapeutic
monitoring and responses.
12. The management of COPD will proceed as usual according to standard clinical practice for
COPD.
Usual Care Control Group. For patients who are randomly allocated to the UC Control Group,
1. The presence of psychiatric co-morbidity will be identified under standard conditions by
usual care team, with the appropriate psychiatric consultation-liaison referrals and
treatment effected as deemed necessary.
2. Treatment and care management of psychiatric and psycho-social problems will include
appropriate pharmacologic and/or non-pharmacologic therapies and psycho-social support,
in accordance with standard recommended guidelines and practices for both COPD and
anxiety/depression.
3. The assessment of trial outcomes performed at 3 or 6 monthly intervals as appropriate
(perceived symptoms of breathlessness, exercise tolerance, spirometric measurement,
smoking cessation, HADS, SGRQ quality of life, acute COPD exacerbations,
rehospitalization(s), emergency department visits, and unscheduled physician visits
etc.) is also performed, but is not an integral part of Usual Care.
4. Ad hoc outpatient follow up visits are scheduled at any appropriate times for
therapeutic and other care monitoring and responses.
5. The management of COPD will proceed as usual according to standard clinical practice for
COPD.
To mimic prevailing conditions of healthcare financing and delivery, payments for referrals
to hospital psychiatrists for treatment, drugs and psychotherapy, regardless of allocation to
IPCL or UC group, will be borne by the patients using existing avenues of health service
financing (Medisave, Medishield, and/or out-of-pockets) as appropriate.
Trial related scheduled assessments of outcome measures All participants in both IPCL and UC
control arms will be assessed at baseline, 3 months, 6 months, 9 months and 12 months for the
following trial related outcomes. We define loss to follow-up (LTFU) as incomplete
ascertainment of the primary outcome for subjects randomized in the trial. Operationally,
LTFU is defined as absence from at least 2 consecutive assessments (>6 months).
Statistical Analysis
Primary effectiveness end-points
- HADS score
- Breathlessness (MRC Index)
- Six-minutes walking distance
- Borg's scale
- FEV1, FEV1/FVC, PEFR, SpO2
- BODE Index
- Smoking quit rates
- Functional health and quality of life (SGRQ scores, CAT score, quality-adjusted life
years (QALY))
- Acute COPD exacerbations
- Emergency department visits
- Unscheduled physician visits
- Re-hospitalization(s)
Secondary effectiveness end points:
- Resource use and direct costs of care:
- 1. Resource use include inpatient service use (No. of times hospitalized and total days
in hospital) , outpatient service use (physician visits consisting of GP visits and
specialist visits,) and medication use( usage of any or specific drug classes)
- 2. Direct costs of care include costs for outpatient medical and mental health care,
inpatient medical and mental health services and medication.
- Mortality
- COPD medication adherence
- Psychiatric medication adherence
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A |